NEW YORK, Jan. 2 (GenomeWeb News) - Lynx Therapeutics today said it has completed a $4 million private financing of common stock and warrants for common stock.

The financing included the sale of 800,000 newly issued shares of common stock at $5.00 per share and the issuance of warrants to purchase 200,000 shares of common stock at an exercise price of $6.25 per share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.